杨森制药的厄达替尼怎么购买？

(Erdafitinib) is an oral fibroblast growth factor receptor (FGFR) inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC). This type of patient has FGFR3 or FGFR2 gene mutations and has disease progression within 12 months after receiving at least one platinum-based chemotherapy regimen (including neoadjuvant or adjuvant platinum-based chemotherapy regimen). The U.S. Food and Drug Administration (FDA) accelerated approval of this drug for marketing on April 12, 2019. This is the first targeted drug approved by the FDA for this indication. At this point, patients can purchase the erdafitinib they need in the United States. Patients in need can contact Medical Travel to purchase medicine overseas.

Developed by Xi'an Janssen Pharmaceutical Co., Ltd., erdafitinib represents the first treatment option for patients with metastatic bladder cancer harboring FGFR gene mutations. Xi'an Janssen Pharmaceutical Co., Ltd. is the largest subsidiary of Johnson & Johnson in China. The company's business includes the production and sales of high-quality pharmaceuticals. Its products mainly cover the fields of gastroenterology, neuropsychiatry, allergy, pain management, anti-infection, biologics and oncology. In addition, the company is also committed to providing health-related services and carrying out public health education.

Erdafitinib from Janssen Pharmaceuticals is a yellow powder that is almost insoluble or insoluble in organic solvents. Its molecular formula is C25H30N6O2 and its relative molecular mass is 446.56. Erdafitinib is a time-dependent inhibitor and inducer of CYP3A4, and its effect on sensitive CYP3A4 substrates is unclear. It is necessary to avoid concurrent use of sensitive CYP3A4 substrates with narrow therapeutic windows.

Erdafitinib is a substrate and inhibitor of P-gp. P-gp inhibitors are not expected to affect clinical efficacy. Avoid administration at least 6 hours before or after administration of P-gp substrates with a narrow therapeutic window.

Recommended hot articles: /newsDetail/96452.html

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.